Aging Hallmarks — What You Can Actually Measure in a Patient

I had a patient last week — 49, healthy — hand me a direct-to-consumer panel showing her telomere length equivalent to a 68-year-old. She wanted to know what to do first. I had no good answer.

That's the right instinct — to pause. The hallmarks of aging framework organizes molecular damage into tiers. The primary hallmarks are the damage itself: genomic instability, telomere attrition, epigenetic drift, loss of proteostasis, and disabled autophagy. The other tiers are the body's responses to that damage. Most panels conflate them.

So telomere length — that's a primary hallmark. Is it actionable?

Epidemiologically, shorter leukocyte telomere length associates with cardiovascular disease and some cancers — that's observational data, no intervention trial has shown that lengthening telomeres improves a clinical endpoint in humans. So: measurable, yes. Actionable as a treatment target, no.

What about the methylation-based pace of aging — her report said 1.09, whatever that means?

That's an epigenetic clock estimate — algorithms trained on DNA methylation patterns, where cytosine bases are chemically modified, to predict biological age. A pace above 1.0 means aging faster than chronological age. Horvath's and DunedinPACE are the validated versions. Associational data with mortality is reasonable. Again, no randomized trial has shown that moving the number improves outcomes.

And the autophagy support score on the same panel?

That one I'd discard. Autophagy — the process by which cells degrade and recycle damaged proteins — has no validated clinical biomarker. That line item is marketed without evidence. Tell her that directly.

Same visit I had a genomic report on a 62-year-old flagging a DNMT3A variant at 4% allele fraction. That's the genomic instability hallmark. Does that one change anything?

That one actually might. DNMT3A mutations at that fraction suggest clonal hematopoiesis of indeterminate potential — CHIP — where a blood stem cell with a somatic mutation expands. The 4% threshold is meaningful: above roughly 2% variant allele fraction on a validated high-depth assay, CHIP is associated with a two-to-fourfold increased cardiovascular risk and elevated hematologic malignancy risk. But the report you described came from standard whole-genome depth — too shallow to confirm it. You need a dedicated high-sensitivity hematology panel before acting.

So I shouldn't counsel the patient on that incidental finding yet?

Correct. Confirm first. If CHIP is confirmed, current ACC guidance supports aggressive cardiovascular risk factor management. There's no approved CHIP-directed therapy yet, though trials are running.

Back to my 49-year-old — is there anything on her panel worth following?

The epigenetic clock is the most defensible research-grade measure of primary hallmark accumulation with prospective mortality data behind it. I'd tell her it's a signal worth noting, not a diagnosis, and that the interventions with the best evidence for slowing epigenetic aging are exercise, sleep, and not smoking — not the supplements her panel vendor sells.

What's the single thing you'd want me to remember walking out?

One primary hallmark has a confirmed clinical workflow right now: genomic instability in the form of CHIP, confirmed on a validated assay, with cardiovascular risk implications and a management path. Everything else in this space is mechanistically real and clinically premature. Order the assay, skip the score.